Ryan J. Linder

Boronic Acids and Derivatives—Probing the Structure–Activity Relationships for Mutagenicity

Marvin M. Hansen, Robert A. Jolly, Ryan J. Linder · Organic Process Research & Development · 2015 · 69 citations

Abstract 1259: Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor

Sheng-Bin Peng, Chong Si, Youyan Zhang et al. · Cancer Research · 2021 · 41 citations

Drug Target, Molecular Biology, Pharmacotherapy +23

Development of Pilot-Scale Continuous Production of an LY2886721 Starting Material by Packed-Bed Hydrogenolysis

Nikolay Zaborenko, Ryan J. Linder, Timothy M. Braden et al. · Organic Process Research & Development · 2015 · 31 citations

Hydrogen Production, Engineering, Hydrogen Generation +17

Synthesis of BACE Inhibitor LY2886721. Part II. Isoxazolidines as Precursors to Chiral Aminothiazines, Selective Peptide Coupling, and a Controlled Reactive Crystallization

Marvin M. Hansen, Daniel J. Jarmer, Enver Arslantas et al. · Organic Process Research & Development · 2015 · 28 citations

Reactive Crystallization, Bioorganic Chemistry, Organic Chemistry +19

Design, Development, and Scale-Up of a Selective <i>meso</i>-Epoxide Desymmetrization Process

David L. Varie, Christopher M. Beck, Sandra K. Borders et al. · Organic Process Research & Development · 2007 · 26 citations

Chemical Engineering, Engineering, Pilot-plant Scale Desymmetrization +15